Effect of Micronized Purified Flavonoid Fraction Containing Hesperidin and Diosmin on Vincristine-Induced Neuropathy in Rats; the Role of Nitric Oxide Pathway.
{"title":"Effect of Micronized Purified Flavonoid Fraction Containing Hesperidin and Diosmin on Vincristine-Induced Neuropathy in Rats; the Role of Nitric Oxide Pathway.","authors":"Nikoo Abharian, Nima Naderi, Noushin Nikray, Mona Khoramjouy, Shokoofe Noori, Hamed Shafaroodi, Mehrdad Faizi","doi":"10.5812/ijpr-154455","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a potential complication that can develop following cancer chemotherapy.</p><p><strong>Objectives: </strong>Due to limited medical interventions for the prevention and management of CIPN caused by vincristine, a painful and common complication, further research to find the mechanisms of CIPN and the development of effective preventive and therapeutic strategies is needed.</p><p><strong>Methods: </strong>We induced CIPN in male Wistar rats by administering intraperitoneal vincristine (VCR) at a dose of 0.1 mg/kg for 10 days. Treatment involved micronized purified flavonoid fraction (MPFF) containing hesperidin and diosmin (MPFF; Daflon<sup>®</sup>) at doses of 50, 100, and 200 mg/kg. Our investigation focused on levels of inflammatory factors (TNF-α, IL-6) in the dorsal root ganglion (DRG) tissue and included a series of behavioral tests: Von Frey, grip strength, rotarod, open field, and hot plate tests. To examine the role of the nitric oxide (NO) pathway in the effects of MPFF on VCR-induced peripheral neuropathy (VIPN), we also tested the effect of L-arginine (100 mg/kg i.p.) as a NO precursor and L-NAME (20 mg/kg i.p.) as a nitric oxide synthase (NOS) inhibitor.</p><p><strong>Results: </strong>Based on our behavioral tests, MPFF (50, 100, 200 mg/kg) effectively reduced some symptoms of VIPN, including mechanical allodynia and hyperalgesia. Notably, TNF-α and IL-6 levels in the DRG tissue of the groups treated with 100 and 200 mg/kg of MPFF showed a significant reduction in inflammatory factors. These results underscore the potential of MPFF and the role of the NO signaling pathway in alleviating neuropathic pain caused by VCR.</p><p><strong>Conclusions: </strong>Micronized purified flavonoid fraction may be an effective treatment for VIPN by reducing mechanical allodynia, thermal hyperalgesia, and TNF-α and IL-6 levels in DRG tissue. The NO pathway may play a role in the effectiveness of MPFF in treating VIPN.</p>","PeriodicalId":14595,"journal":{"name":"Iranian Journal of Pharmaceutical Research","volume":"24 1","pages":"e154455"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297021/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Pharmaceutical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5812/ijpr-154455","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a potential complication that can develop following cancer chemotherapy.
Objectives: Due to limited medical interventions for the prevention and management of CIPN caused by vincristine, a painful and common complication, further research to find the mechanisms of CIPN and the development of effective preventive and therapeutic strategies is needed.
Methods: We induced CIPN in male Wistar rats by administering intraperitoneal vincristine (VCR) at a dose of 0.1 mg/kg for 10 days. Treatment involved micronized purified flavonoid fraction (MPFF) containing hesperidin and diosmin (MPFF; Daflon®) at doses of 50, 100, and 200 mg/kg. Our investigation focused on levels of inflammatory factors (TNF-α, IL-6) in the dorsal root ganglion (DRG) tissue and included a series of behavioral tests: Von Frey, grip strength, rotarod, open field, and hot plate tests. To examine the role of the nitric oxide (NO) pathway in the effects of MPFF on VCR-induced peripheral neuropathy (VIPN), we also tested the effect of L-arginine (100 mg/kg i.p.) as a NO precursor and L-NAME (20 mg/kg i.p.) as a nitric oxide synthase (NOS) inhibitor.
Results: Based on our behavioral tests, MPFF (50, 100, 200 mg/kg) effectively reduced some symptoms of VIPN, including mechanical allodynia and hyperalgesia. Notably, TNF-α and IL-6 levels in the DRG tissue of the groups treated with 100 and 200 mg/kg of MPFF showed a significant reduction in inflammatory factors. These results underscore the potential of MPFF and the role of the NO signaling pathway in alleviating neuropathic pain caused by VCR.
Conclusions: Micronized purified flavonoid fraction may be an effective treatment for VIPN by reducing mechanical allodynia, thermal hyperalgesia, and TNF-α and IL-6 levels in DRG tissue. The NO pathway may play a role in the effectiveness of MPFF in treating VIPN.
期刊介绍:
The Iranian Journal of Pharmaceutical Research (IJPR) is a peer-reviewed multi-disciplinary pharmaceutical publication, scheduled to appear quarterly and serve as a means for scientific information exchange in the international pharmaceutical forum. Specific scientific topics of interest to the journal include, but are not limited to: pharmaceutics, industrial pharmacy, pharmacognosy, toxicology, medicinal chemistry, novel analytical methods for drug characterization, computational and modeling approaches to drug design, bio-medical experience, clinical investigation, rational drug prescribing, pharmacoeconomics, biotechnology, nanotechnology, biopharmaceutics and physical pharmacy.